SA
Log In
RVMD
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
22 analysts·High coverage
75
Score
21 Buy (95%)1 Hold (5%)0 Sell (0%)
Rating Breakdown
Strong Buy
15%
Buy
2091%
Hold
15%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$73.00
-51.4%
Consensus
$163.50
+8.8%
Bull
$200.00
+33.0%
12-Month Target Range22 analysts
$73.00$163.50$200.00
Current $150.33Consensus
Current Price
$150.33
Upside to Consensus
$13.17

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+678.98%
EPS—
FY2028
Rev+143.64%
EPS—
FY2029
Rev+104.02%
EPS—

Earnings Surprises

Recent Analyst Actions

Apr 14, 2026Guggenheim
Revolution Medicines price target raised to $175 from $160 at Guggenheim
Target:$175.00
+28.4%from $136.30
Apr 14, 2026Evercore ISI
Revolution Medicines price target raised to $200 from $140 at Evercore ISI
Target:$200.00
+46.7%from $136.30
Apr 14, 2026RBC Capital
Revolution Medicines price target raised to $162 from $140 at RBC Capital
Target:$162.00
+18.9%from $136.30
Apr 14, 2026H.C. Wainwright
Revolution Medicines price target raised to $169 from $73 at H.C. Wainwright
Target:$169.00
+24.0%from $136.30
Apr 13, 2026Oppenheimer
Revolution Medicines price target raised to $165 from $150 at Oppenheimer
Target:$165.00
+22.3%from $134.88
Feb 26, 2026Wells Fargo
Revolution (RVMD) PT Raised to $144 at Wells Fargo
Target:$144.00
+39.5%from $103.24
Jan 27, 2026Oppenheimer
Revolution Medicines price target raised to $150 from $75 at Oppenheimer
Target:$150.00
+53.4%from $97.78
Jan 22, 2026UBS
Revolution Medicines price target raised to $170 from $85 at Stifel
Target:$170.00
+44.3%from $117.84
Jan 21, 2026RBC Capital
Revolution Medicines price target raised to $140 from $77 at RBC Capital
Target:$140.00
+20.5%from $116.22
Jan 20, 2026Guggenheim
Revolution Medicines price target raised to $160 from $92 at Guggenheim
Target:$160.00
+33.0%from $120.28
Jan 13, 2026Goldman Sachs
Goldman Sachs on Revolution (RVMD): 'Catalyst-rich 2026 underpins the breadth of the clinical portfolio'
Target:$73.00
-39.1%from $119.95
Jan 13, 2026Mizuho Securities
Revolution Medicines price target raised to $143 from $90 at Mizuho
Target:$143.00
+22.0%from $117.17
Jan 9, 2026Wedbush
Revolution Medicines price target raised to $147 from $80 at Wedbush
Target:$147.00
+30.5%from $112.68
Nov 3, 2025RBC Capital
RBC Capital Starts Revolution (RVMD) at Outperform
Target:$77.00
+30.9%from $58.84
Oct 17, 2025National Bank
Revolution Medicines price target raised to $80 from $78 at BofA
Target:$80.00
+48.7%from $53.81
Oct 17, 2025Raymond James
Revolution Medicines price target raised to $76 from $72 at Raymond James
Target:$76.00
+53.0%from $49.68
Oct 15, 2025Stifel Nicolaus
Revolution Medicines resumed with a Buy at Stifel
Target:$85.00
+71.5%from $49.56
Sep 5, 2025Truist Financial
Revolution Medicines initiated with a Buy at Truist
Target:$99.00
+144.4%from $40.50
Aug 19, 2025Piper Sandler
Piper starts Revolution Medicines at Overweight on daraxonrasib potential
Target:$75.00
+105.1%from $36.56
May 14, 2025H.C. Wainwright
Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright
Target:$72.00
+71.9%from $41.88
Apr 1, 2025Stifel Nicolaus
Revolution Medicines price target lowered to $64 from $78 at Stifel
Target:$64.00
+90.4%from $33.62
Jan 8, 2025UBS
Revolution Medicines price target raised to $71 from $65 at UBS
Target:$71.00
+60.2%from $44.33
Nov 7, 2024Piper Sandler
Revolution (RVMD) PT Raised to $70 at Piper Sandler
Target:$70.00
+24.8%from $56.09
Nov 4, 2024H.C. Wainwright
Revolution (RVMD) PT Raised to $62 at H.C. Wainwright
Target:$62.00
+11.0%from $55.87
Oct 28, 2024Guggenheim
Revolution Medicines price target raised to $82 from $72 at Guggenheim
Target:$82.00
+74.6%from $46.96

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance